Drug Trial Radar · NCT07174583
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
262
Planned (sponsor's estimate)
Start
Oct 14, 2025
Primary completion
Jul 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- IDEAYA BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Conditions
- Small-cell Lung Cancer
- Neuroendocrine Carcinomas
- Solid Tumor Show to Express DLL3
Interventions
IDE849Drug
IV administration
durvalumabDrug
IV administration
IDE161Drug
oral administration
CarboplatinDrug
IV administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1A: Safety and Tolerability of IDE849 (Monotherapy)Time frame: approximately 4 years total study duration
- Part 1B: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161Time frame: approximately 4 years total study duration
- Part 2: Safety and Tolerability of IDE849 (Monotherapy Dose Expansion)Time frame: approximately 4 years total study duration
- Part 2: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161 or durvalumab + carboplatin (Dose Expansion)Time frame: approximately 4 years total study duration
- Part 2: Objective Response Rate (ORR) and Investigator Assessment of IDE849 ORR per RECIST 1.1Time frame: approximately 4 years total study duration
- Part 2: Duration of Response (DOR) and Investigator Assessment of IDE849 DOR per RECIST 1.1Time frame: approximately 4 years total study duration
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Sarah Cannon Research Institute at HealthONE
Denver, Colorado · Recruiting
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida · Recruiting
Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office
Fort Wayne, Indiana · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
The Cancer and Hematology Centers
Grand Rapids, Michigan · Recruiting
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York · Recruiting
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Sarah Cannon Research Institute - Oncology Partners
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Oncology Consultants, PA- Houston
Houston, Texas · Recruiting
Next Oncology Dallas
Irving, Texas · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
Swedish Cancer Institute
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.